-ichi Inui. Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor ␣.
DIETARY PROTEINS ARE DEGRADED into a mixture of free amino acids and small peptides. A large number of studies have provided evidence that the absorption of protein digestion products in the small intestine occurs primarily in the form of small peptides rather than amino acids (22) . Thus intestinal peptide transport is of major nutritional significance for the effective absorption of dietary amino nitrogen. Cellular uptake of di-and tripeptides is mediated via H ϩ -coupled peptide cotransporter 1 (PEPT1, SLC15A1), which is primarily expressed in the small intestine and slightly in the kidney (5) . Because of its broad substrate specificity, PEPT1 can accept several peptidelike drugs such as oral ␤-lactam antibiotics (39) and plays important roles not only as a nutrient transporter but also as a drug transporter. A large number of functional studies using heterologous expression systems have demonstrated the molecular nature of its transport characteristics (6, 15, 20, 24) . Furthermore, many studies have also been directed toward the regulation of PEPT1. For example, it has been reported that intestinal PEPT1 is regulated by various factors (1) , including dietary conditions (28, 35, 42) , hormones [insulin (10) , thyroid hormone (2)], epidermal growth factor (27) , some pharmacological agents (3, 9) , and diurnal rhythm (29) .
Among these factors, the dietary regulation of intestinal PEPT1 has been extensively investigated (14, 26, 28, 30, 31, 35, 42) . It has been reported that short-term starvation markedly increased the amount of PEPT1 mRNA and protein expression (14, 30, 42) and uptake activity of dipeptides (42) . The induction of PEPT1 expression might be an adaptive response against fasting for efficient absorption immediately after food is given again. This fasting-induced expression of PEPT1 altered the pharmacokinetic profiles of some drugs. Fasting increased the transport of the ␤-lactam antibiotic cefadroxil in an in situ loop experiment (26) and also increased pharmacokinetic parameters such as maximum plasma concentration and area under the plasma concentration-time curve of the ␤-lactam antibiotic ceftibuten in vivo (30) .
Although these studies demonstrated the functional aspects of PEPT1 augmentation, the regulatory mechanisms remain to be clarified. In the present study, we assume that some metabolic signals direct this regulation. In the liver, an adaptive response to fasting has been well characterized (43) . During fasting, lipolysis of stored triglycerides in adipose tissue is strongly activated, resulting in marked increase in plasma free fatty acid level. The released fatty acids are delivered to the liver, where they undergo ␤-oxidation for energy production. The peroxisome proliferator-activated receptors (PPAR␣, -␤/␦, and -␥) are a family of nuclear receptors activated by fatty acid ligands (7, 12) . PPAR␣ acts as a nutritional state sensor and plays a pivotal role in the control of this adaptive response (16, 21) by inducing the transcription of genes such as the peroxisomal and mitochondrial ␤-oxidation pathways. Accordingly, PPAR␣ is principally expressed in organs with a high capacity for fatty acid oxidation, such as heart, skeletal muscle, liver, and kidney. However, PPAR␣ is also expressed in the small intestine (7) and is increased by fasting (8) . This raises the possibility that PPAR␣ might be responsible for the augmentation of PEPT1 during fasting. In the present study, we have investigated this possibility by examining PPAR␣ activation through synthetic ligand and expression profiles of intestinal PEPT1 in fed and fasted PPAR␣-null mice. (38, 40) .
MATERIALS AND METHODS

Materials
Animal studies. Animal studies were performed in accordance with the Guidelines for Animal Experiments of Kyoto University. All protocols were previously approved by the Animal Research Committee, Graduate School of Medicine, Kyoto University (MedKyo 05189). Male Wistar rats (8 wk old) were obtained from Japan SLC. Male PPAR␣-null mice (B6.129S4-Ppar␣ tm1Gonz N12) and wild-type mice (C57BL/6) (8 wk old) were purchased from Taconic (Germantown, NY). The animals were fed a normal chow ad libitum except for the fasting experiments. In all experiments, the animals had free access to water. For determination of the effects of fasting, food was removed from cages 48 h before the animals were killed. For determination of the effect of PPAR␣ ligand, fed rats were treated with WY-14643 (50 mg ⅐ 5 ml Ϫ1 ⅐ kg Ϫ1 ⅐ day Ϫ1 , suspended in 0.5% methyl cellulose solution) or vehicle (5 ml/kg) by oral gavage for 5 days and killed after an additional 24 h. The small intestine (duodenum and upper part of the jejunum) was removed from the rats or mice under anesthesia. The kidney cortex was also removed from mice. The scraped intestinal mucosa and kidney cortex were rapidly frozen in liquid nitrogen for later preparation of total RNA.
Measurement of level of blood glucose and serum free fatty acids. Blood glucose level was quantified with the FreeStyle blood glucose monitoring system (Nipro, Osaka, Japan). Serum free fatty acid level was quantified with an enzymatic colorimetric assay (free fatty acid, Half-micro test; Roche Diagnostics, Penzberg, Germany).
Real-time PCR. Total RNA was isolated from Caco-2 cells, intestinal mucosa of rats and mice, and mice kidney cortex with the RNeasy Mini Kit (Qiagen, Hilden, Germany). Isolated total RNA (250 or 500 ng) was reverse transcribed, and the reaction mixtures were used for real-time PCR. Real-time PCR was performed with an ABI PRISM 7700 (Applied Biosystems, Foster City, CA) in a total volume of 20 l containing a 2-l aliquot of cDNA, 0.5 M forward and reverse primers, 0.1 M TaqMan probe, and 10 l of TaqMan Universal PCR Master Mix (Applied Biosystems) under the following conditions: 50 cycles of 95°C for 15 s and 60°C for 60 s. The forward and reverse primers for mouse PEPT1 were 5Ј-CGTGCACGTAG-CACTGTCCAT-3Ј (positions 388 -408) and 5Ј-GGCTTGATTC-CTCCTGTACCA-3Ј(positions 433-453), respectively. The forward and reverse primers for rat PEPT1 were 5Ј-TGCACGTAGCACT-GTCCATGA-3Ј (positions 359 -379) and 5Ј-CAGGGCTTGATTC-CTCCTGTAC-3Ј (positions 425-404), respectively. The sequence of the TaqMan probe was 5Ј-(6-FAM)TTGGCCTGGCCCTGATAGC-CC(TAMRA)-3Ј, corresponding to positions 411-432 for mice, and 5Ј-(6-FAM)CGGCCTGGCCCTGATAGCCCT(TAMRA)-3Ј, corresponding to positions 381-404 for rats. The primer probe sets used for human PEPT1 (41) and rat Na ϩ -glucose cotransporter 1 (SGLT1) (13) were previously designed. The primer probe sets used for mouse and rat PPAR␣, mouse acyl-CoA oxidase (ACOX), rat Sp1, and rat Cdx2 were predeveloped TaqMan Assay Reagents (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was also measured as an internal control with GAPDH Control Reagent (Applied Biosystems).
Data analysis. Data are expressed as means Ϯ SE. The statistical significance of differences between the groups was analyzed with one-way ANOVA followed by Scheffé F post hoc testing in the experiment using Caco-2 cells and multiple concentrations of WY-14643 as a ligand. In other experiments, the nonpaired t-test was used. Two or three experiments were conducted, and representative results are shown.
RESULTS
Fasting-induced expression of intestinal PEPT1 is accompanied by increased mRNA level of PPAR␣ in rats.
In general, energy depletion by fasting causes a shift in whole body fuel utilization from glucose and fat in the fed state to almost exclusively fat. Under our experimental conditions, 48-h fasting led to reductions in body weight and blood glucose level and dramatic increment in serum free fatty acid level, reflecting the metabolic switching mentioned above (Fig. 1) . Under this condition, we determined mRNA levels of intestinal PEPT1 and PPAR␣ (Fig. 2) . The transcription factor Sp1 and caudalrelated homeobox protein Cdx2 were also measured because we recently demonstrated that PEPT1 is transcriptionally regulated by Sp1 and Cdx2 (33, 34) . As expected, fasting significantly induced mRNA levels of PEPT1, consistent with our previous result (30) . The expression level of PPAR␣ was increased to twofold by fasting, whereas the increments in Sp1 and Cdx2 were smaller than that in PPAR␣.
Expression of PEPT1 mRNA is induced by PPAR␣ ligand WY-14643 in Caco-2 cells. To assess the potential involvement of PPAR␣ in PEPT1 expression, we treated an intestinal model system, Caco-2 cells just before and after confluence, for 24 h with the PPAR␣ ligand WY-14643 and measured the expression levels of PEPT1 mRNA and the activity of [ 3 H]Gly-Sar uptake (Fig. 3) . PEPT1 mRNA expression levels and the activity of [ 3 H]Gly-Sar uptake were significantly increased in response to WY-14643 in the cells of both stages. Thus it was suggested that the induction of PEPT1 mRNA by WY-14643 led to a concomitant increase of the transport function. Next, Fig. 1 . Effects of fasting on body weight (A), blood glucose (B), and serum free fatty acids (C) in rats. Blood glucose and serum free fatty acid levels in 48-h fasted or fed rats were determined as described in MATERIALS AND METHODS. Data are means Ϯ SE for 5 rats. **Significantly different from fed rats (P Ͻ 0.01).
Caco-2 cells were treated with the PPAR␣ ligand WY-14643 and increasing concentrations of the PPAR␥ ligand pioglitazone and the PPAR␤/␦ ligand GW-501516 (Fig. 4) . The activity of [ 3 H]Gly-Sar uptake increased only when PPAR␣ ligand WY-14643 was administered.
Effect of WY-14643 on expression levels of intestinal PEPT1 mRNA in rats.
We subsequently administered WY-14643 (50 mg/kg) orally to fed rats for 5 days to examine the effect of PPAR␣ ligand on PEPT1 expression in vivo. For comparison, the mRNA levels of SGLT1 were also determined. SGLT1 is expressed at the brush-border membranes of intestinal epithelial cells (11) as PEPT1 but is reported to show no significant change in its expression level during fasting (14) . As expected, mRNA levels of PEPT1 were significantly increased by WY-14643, whereas those of SGLT1 were not changed (Fig. 5) .
Effect of fasting on expression levels of intestinal PEPT1 in PPAR␣-null mice.
To confirm the contribution of PPAR␣ to fasting-induced PEPT1 expression, we measured mRNA levels of PEPT1 in the small intestine of wild-type and PPAR␣-null mice (Fig. 6) . Fasting induced the expression of PEPT1 and PPAR␣ in wild-type mice as in rats, although the induction of PPAR␣ was not statistically significant. In contrast, this fasting response of PEPT1 was completely abolished in PPAR␣-null mice, indicating the critical role of PPAR␣ in this response.
Effect of fasting on expression levels of renal PEPT1 in PPAR␣-null mice. PEPT1 is also expressed in the kidney, although its expression level is much lower than that in the small intestine. Thus we investigated the effect of fasting on expression levels of PEPT1 and PPAR␣ in the kidney (Fig.  7) . For comparison, mRNA levels of ACOX, which is a peroxisomal ␤-oxidation enzyme and a representative PPAR␣ target gene, were simultaneously determined. In contrast to the intestine, renal PEPT1 was not induced by fasting in either wild-type or PPAR␣-null mice, which is in agreement with our previous result in rats (30) . ACOX expression was markedly enhanced, although the PPAR␣ level did not show significant elevation. These results suggested that the lack of fasting-induced response of renal PEPT1 was not due to insufficient levels of endogenous ligands or PPAR␣. Fig. 2 . Effects of fasting on mRNA levels of peptide cotransporter 1 (PEPT1), peroxisome proliferator-activated receptor (PPAR)␣, Sp1, and Cdx2 in rat small intestine. Total RNA was isolated from the small intestine of 48-h fasted or fed rats, transcribed to cDNA, and subjected to real-time PCR analysis. The results corrected by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels are means Ϯ SE for 5 rats. **Significantly different from fed rats (P Ͻ 0.01). 
DISCUSSION
In the present study, we investigated the regulatory mechanism underlying the augmentation of intestinal PEPT1 in fasting. In agreement with previous results (4, 8) , it was confirmed that the serum concentration of free fatty acids and the expression level of intestinal PPAR␣ mRNA were increased under our experimental condition. We showed that PPAR␣ played a critical role in the augmentation of intestinal PEPT1 as a fasting response mainly through PPAR␣-null mice. In support of the knockout mouse data, we used Caco-2 cells to show that the PPAR␣ ligand WY-14643 upregulated PEPT1, because Caco-2 cells expressed endogenous PPAR␣ (data not shown). Several studies have used Caco-2 cells as an intestinal model for activating PPAR target genes by synthetic PPAR␣ ligands (19, 32, 37) . Furthermore, the effect of WY-14643 on PEPT1 expression was also observed in vivo in rats. These findings led us to speculate that elevated free fatty acids serve as a metabolic signal and activate intestinal PPAR␣, resulting in the augmentation of PEPT1 in an adaptive response to fasting.
With regard to the roles of PPAR␣ in the small intestine, there are several studies. PPAR␣ is reported to be involved in lipid absorption through regulation of fatty acid binding protein (7) . In addition, PPAR␣ influences cholesterol absorption through modulation of ATP binding cassette transporter A1 activity in the intestine (18) . PPAR␣ also regulates other intestinal genes such as CYP1A1 (32) , bile acid binding protein (19) , retinol-binding protein (37) , and 17␤-hydroxysterol dehydrogenase type 11 (25) . The presented function of PPAR␣, i.e., augmentation of PEPT1, is quite different from those previously demonstrated from the point of view that peptide absorption was implicated as a target. In fasting, sloughing of mucosal cells into the intestinal lumen is observed (23) , resulting in atrophy of mucosa and decreased mucosal weight. It may be possible to speculate that increased PEPT1 minimizes the loss of nitrogen by efficient absorption of small peptides derived from sloughing cells or secreted hormones. Furthermore, induced PEPT1 will lead to efficient absorption of peptides immediately after food is given again. It has also Fig. 5 . mRNA levels of PEPT1, Na ϩ -glucose cotransporter (SGLT)1, and GAPDH in the small intestine of rats dosed with WY-14643 (50 mg/kg) for 5 days. Total RNA was isolated from the small intestine, transcribed to cDNA, and subjected to real-time PCR analysis. Data are means Ϯ SE for 3 rats. *Significantly different from control (P Ͻ 0.05). Fig. 6 . mRNA levels of PEPT1 and PPAR␣ in the small intestine of fasted or fed wild-type (ϩ/ϩ) and PPAR␣-null (Ϫ/Ϫ) mice. Total RNA was isolated from the small intestine of 48-h fasted or fed mice, transcribed to cDNA, and subjected to real-time PCR analysis. Data corrected by GAPDH levels are means Ϯ SE for 6 mice. *Significantly different from fed mice of the same genotype (P Ͻ 0.05). been reported that PPAR␣ downregulates the hepatic genes involved in amino acid metabolism, leading to an overall decrease of amino acid degradation (17) . It seems reasonable to suppose that PPAR␣ functions to minimize the loss of body amino acids both by suppressing amino acid degradation and by increasing peptide absorption during fasting.
In contrast to the small intestine, no PEPT1 induction was observed in the kidney, suggesting different regulatory mechanisms for PEPT1 between them. This cannot be explained solely by the lack of activation of renal PPAR␣, because the expression of the representative PPAR␣ target gene, ACOX, was markedly increased. PPAR␣ and free fatty acids may be necessary but not sufficient for the induction of renal PEPT1.
In our previous and present study, the fasting response of PEPT1 was discussed mainly from the findings obtained in rats or mice. In humans, WY-14643 induced the expression of PEPT1 in a human intestinal cell line, Caco-2. This result, together with the fact that plasma free fatty acids are also increased during fasting in humans (36) , suggested that a similar regulation of PEPT1 by PPAR␣ might exist also in humans. To test the possibility that PPAR␣ directly regulates the human PEPT1 promoter, we searched for the potential PPAR response element (PPRE) on the promoter as far as 10 kb upstream of the transcription start site and found several proposed PPREs. However, none of these sites, which were subcloned upstream of the PEPT1 proximal promoter, enhanced basal promoter activity in response to WY-14643 treatment in Caco-2 cells (data not shown). Alternatively, it is possible that PPAR␣ stimulates the expression of other transcription factors that regulate PEPT1. mRNA levels of Sp1 and Cdx2 were increased in fasted rats. However, these factors may not be responsible for the augmentation of PEPT1 by PPAR␣ because the PEPT1 promoter activity responsive to Sp1 or Cdx2 was not altered by WY-14643 treatment (data not shown). The functional PPRE and/or other regulatory region related to PPAR␣ may be located in more distal regions or intronic regions.
The observation that PPAR␣ regulates PEPT1 expression raises the question of whether the administration of PPAR␣ agonist increases PEPT1 function in the clinical situation. This issue is important from the viewpoint of clinical drug-drug interaction because PPAR␣ ligands belonging to the fibrate class have been used widely as hypolipidemic drugs. Oral dosing of WY-14643 in rats resulted in increase of PEPT1 expression. It is unclear whether clinically used PPAR␣ ligands affect the expression of human intestinal PEPT1 in vivo. Further studies will be needed to estimate the change in the clinical pharmacokinetics of PEPT1 substrates and the impact on its therapeutic effects.
In conclusion, we demonstrated that PPAR␣ plays a critical role in the augmentation of PEPT1 during fasting. We propose a novel function of PPAR␣ in the small intestine, that is, the regulation of nitrogen absorption through PEPT1 as an adaptive response to fasting. 
